Mendus

4,95

SEK

-0,5 %

Mindre end 1K følgere

IMMU

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Ownership

Investor consensus

-0,5%

-17,51%

-38,12%

-36,55%

-48,1%

-47,84%

-86,54%

-96,59%

-96,26%

Mendus develops cancer immunotherapies with a focus on the prevention of tumor recurrence, the leading cause of cancer-related deaths globally. Indications include acute myeloid leukemia, ovarian cancer and soft tissue sarcomas. The company previously went by the name Immunicum and was renamed Mendus following the merger with the Dutch private company DCprime in 2021. Mendus today has its headquarters in Stockholm and its operational activities in Leiden, The Netherlands.

Markedsværdi

249,28 mio. SEK

Aktieomsætning

160,77 t SEK

Omsætning

-

EBIT %

-

P/E

-

Udbytteafkast, %

-

Latest research

Seneste analyse

Released: 20.11.2024

Seneste omfattende analyse

Released: 10.04.2024

Finanskalender

6.5

2025

Generalforsamling '25

6.5

2025

Delårsrapport Q1'25

22.8

2025

Delårsrapport Q2'25

Alle

Analyse

Selskabspræsentationer

Selskabsmeddelelser

Eksterne analyser

ViserAlle indholdstyper

Mendus, Audiocast with teleconference, Q1'25

Videopræsentation6.5.2025, 12.00

Mendus, Audiocast with teleconference, Q1'25

Selskabsmeddelelse15.4.2025, 06.00

Mendus publishes Annual Report for 2024

Pressemeddelelse4.4.2025, 06.00

Data supporting the use of Mendus’ DCOne platform to improve production of ovarian cancer TIL therapies presented at ITOC conference

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Selskabsmeddelelse2.4.2025, 06.00

Notice of Annual General Meeting in Mendus AB (publ)

Pressemeddelelse6.3.2025, 07.00

Mendus to participate in investor and industry conferences in March

Pressemeddelelse21.2.2025, 07.00

First patient enrolled in the AMLM22-CADENCE trial with Mendus’ product vididencel

Pressemeddelelse14.2.2025, 08.49

Redeye: Mendus Q4 2024 - Getting closer to pivotal-stage readiness

Mendus, Audiocast with teleconference, Q4'24

Videopræsentation13.2.2025, 07.30

Mendus, Audiocast with teleconference, Q4'24

Selskabsmeddelelse13.2.2025, 07.00

Mendus AB Year-end Report 2024

Pressemeddelelse10.2.2025, 07.00

Invitation to presentation of Mendus’ year-end report for 2024

Pressemeddelelse4.2.2025, 07.00

Mendus to participate in investor and industry conferences in February

Pressemeddelelse7.1.2025, 07.00

Mendus to participate in several investor and industry conferences in January

Pressemeddelelse2.1.2025, 07.00

FDA and EMA feedback endorses vididencel registration trial preparations

Pressemeddelelse23.12.2024, 17.00

Mendus announces termination by Institut Bergonié of the collaboration agreement to study ilixadencel in soft tissue sarcomas

Pressemeddelelse18.12.2024, 07.00

Mendus and UMCG announce positive topline data from the ALISON trial with vididencel in ovarian cancer

Pressemeddelelse9.12.2024, 07.00

Updated data from the ADVANCE II Phase 2 trial presented at ASH demonstrate durable survival of AML patients treated with vididencel

Regulation of drug development

Analytikerkommentar3.12.2024, 10.21 af

Regulation of drug development

The third part in our series of articles on investing in Life Science companies deals with regulatory issues. Regulatory processes are demanding and time-consuming, and failure to comply can be disastrous for a drug development company.

Faron Pharmaceuticals Herantis Pharma Orion Mendus Modulight

Mendus: We are discontinuing coverage

Analyse20.11.2024, 17.00 af

Mendus: We are discontinuing coverage

We are discontinuing our coverage of Mendus as the company has terminated the equity research agreement. Consequently, we will no longer be giving a target price (was SEK 14) or a recommendation (was Accumulate) for the stock.

Pressemeddelelse11.11.2024, 15.20

Redeye: Mendus Q3 2024 - Minor catalysts in Q4 2024e, CADENCE in focus

Mendus Q3'24: Building basis for a pivotal trial

Analyse11.11.2024, 06.48 af

Mendus Q3'24: Building basis for a pivotal trial

In Q3, Mendus reported bringing ilixadencel back into clinical development, opening research centers for the CADENCE trial and progressing in building Phase III readiness.

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.